London, UK: We are extremely delighted to announce that o2h Ventures backed Alevin Therapeutics, a University of Nottingham spinout, won the Best Biotech Startup Company award at the renowned OBN Awards 2022.

Alevin Therapeutics wins OBN Awards

Alevin Therapeutics is developing a platform of novel small molecule RGD integrin inhibitors having broad therapeutic applications in areas of high unmet clinical need – fibrosis, kidney disease, and cancer – with the most advanced asset being an inhaled drug for the treatment of lung fibrosis.

For more information, please visit: https://obn.glueup.com/event/obn-awards-2022-52570/2022-winners—finalists.html  

Media Contact:

Juhi Shah

Marketing Manager

juhi.shah@o2h.com

o2h-ventures